Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Aethlon Medical (AEMD) EBITDA (2016 - 2025)

Aethlon Medical (AEMD) has disclosed EBITDA for 15 consecutive years, with -$2.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, EBITDA rose 19.39% year-over-year to -$2.0 million, compared with a TTM value of -$9.3 million through Mar 2025, up 26.07%, and an annual FY2025 reading of -$13.4 million, down 9.74% over the prior year.
  • EBITDA was -$2.0 million for Q1 2025 at Aethlon Medical, down from -$1.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.8 million in Q4 2024 and bottomed at -$3.8 million in Q1 2022.
  • Average EBITDA over 5 years is -$2.7 million, with a median of -$2.6 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 82.54% in 2022, then surged 49.13% in 2024.
  • Year by year, EBITDA stood at -$2.5 million in 2021, then fell by 12.73% to -$2.8 million in 2022, then dropped by 25.17% to -$3.6 million in 2023, then soared by 49.13% to -$1.8 million in 2024, then fell by 10.43% to -$2.0 million in 2025.
  • Business Quant data shows EBITDA for AEMD at -$2.0 million in Q1 2025, -$1.8 million in Q4 2024, and -$2.9 million in Q3 2024.